TopiVert is a private, clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye.

Our lead GI programme, TOP1288 for the treatment of ulcerative colitis is currently in a Phase 2a proof-of-concept study in Europe using a rectal formulation, while a Phase 1 study with an oral formulation of TOP1288, as the intended commercial presentation, is due to start in early 2017. In parallel our lead ophthalmology programme, TOP1630, is due to start a Phase 1/2a proof-of-concept study in dry eye syndome patients in the US in early 2017. Data from all three clinical studies is expected to be available in the second half of 2017. 

"We aim to change the lives of millions of people around the world suffering with serious diseases such as inflammatory bowel disease and dry eye disease, both areas with high unmet medical needs"

Hamish Cameron, Chairman of TopiVert

NSKIs are novel small molecules characterised by broad efficacy and an excellent safety profile. Each NSKI has potent activity against a select range of key kinases that play pivotal roles in multiple inflammatory pathways and has resulted in a broad synergistic effect in models of both innate and adaptive immunity. NSKIs also have non-systemic bioavailability, such that their activity is focused at the local site of disease. Together, these attributes make NSKIs ideally adapted as treatments for inflammatory diseases where long-term therapy demands a sustained effect along with high safety and tolerability. TopiVert has chosen to apply its NSKI technology to gastrointestinal and eye diseases, which are particularly amenable to topical applications and where there are major unmet needs for improved therapy.

Our high quality science and experienced management team are backed by industry leading investors. Learn more about who we are, what we are doing and what drives us forward...